Literature DB >> 31650346

Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?

Youngjee Choi1, Katherine C Smith2,3, Aishwarya Shukla4, Amanda L Blackford3, Antonio C Wolff3, Elissa Thorner3, Kimberly S Peairs4,3, Walid El Ayass5, Patricia Njoku4, Katie Papathakis3, Carol D Riley3, Nelli Zafman3, Fariba Asrari4, Melissa Camp4, Jean L Wright4, Nancy J Mayonado5, Sharon M White2, Claire F Snyder4,2,3.   

Abstract

PURPOSE: Survivorship care plans (SCPs) provide key information about cancer treatment history and follow-up recommendations. We describe the completeness of breast cancer SCPs and evaluate guideline concordance of follow-up recommendations.
METHODS: We analyzed 149 breast cancer SCPs from two sites, abstracting demographics, cancer/treatment details, surveillance plans, and health promotion advice. SCP recommendations and provided information were compared to American Cancer Society/American Society of Clinical Oncology and National Comprehensive Cancer Network guidelines.
RESULTS: SCP information provided in > 90% of the plans included patient age; relevant providers; cancer stage; treatment details; and physical exam, mammogram, and health promotion recommendations. SCP components completed less frequently included post-treatment symptoms/side effects (67%). All SCPs at the community site were uniform but had the potential for oversurveillance if visits occurred every 3 months in years 1-2 or every 6 months in years 3-5 with multiple cancer providers. The academic site recommended three predominant patterns of follow-up: (1) primary care provider every 6-12 months; (2) cancer team every 3-6 months (year 1), every 6-12 months (years 4-5); and (3) alternating oncology providers every 3-6 months (years 1-2) then every 6 months. Compared to guidelines, these patterns recommend under- and oversurveillance at various times. Mammography recommendations showed guideline concordance (annual) for 84%, oversurveillance for 10%, and were incomplete for 6%. SCPs of only 12/79 (15%) women on aromatase inhibitors recommended guideline-concordant bone density testing.
CONCLUSIONS: SCP content is more complete for demographic and treatment summary information but has follow-up recommendation gaps. Efforts to improve follow-up recommendations are needed.

Entities:  

Keywords:  Breast cancer; Cancer survivorship; Guideline concordance; Survivorship care plan

Year:  2019        PMID: 31650346     DOI: 10.1007/s10549-019-05480-w

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  Use and impact of breast cancer survivorship care plans: a systematic review.

Authors:  Abhishek Joshi; Sarah Larkins; Rebecca Evans; Nishila Moodley; Amy Brown; Sabe Sabesan
Journal:  Breast Cancer       Date:  2021-06-19       Impact factor: 4.239

Review 2.  Breast Cancer Survivorship: the Role of Rehabilitation According to the International Classification of Functioning Disability and Health-a Scoping Review.

Authors:  Monica Pinto; Dario Calafiore; Maria Carmela Piccirillo; Massimo Costa; Ozden Ozyemisci Taskiran; Alessandro de Sire
Journal:  Curr Oncol Rep       Date:  2022-04-11       Impact factor: 5.945

3.  Barriers and engagement in breast cancer survivorship wellness activities.

Authors:  Kristin L Szuhany; Matteo Malgaroli; Gabriella Riley; Carly D Miron; Rebecca Suzuki; Jae Hyung Park; Jane Rosenthal; Abraham Chachoua; Marleen Meyers; Naomi M Simon
Journal:  Breast Cancer Res Treat       Date:  2021-06-07       Impact factor: 4.624

4.  Simplifying Survivorship Care Planning: A Randomized Controlled Trial Comparing 3 Care Plan Delivery Approaches.

Authors:  Claire Snyder; Youngjee Choi; Amanda L Blackford; Jennifer DeSanto; Nancy Mayonado; Susan Rall; Sharon White; Janice Bowie; David E Cowall; Fabian Johnston; Robert L Joyner; Joan Mischtschuk; Kimberly S Peairs; Elissa Thorner; Phuoc T Tran; Antonio C Wolff; Katherine C Smith
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 11.816

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.